Pyrazoles As Anti-inflammatory and Analgesic Agents: and Studies

Overview

Journal Antiinflamm Antiallergy Agents Med Chem

Publisher Bentham Science Publishers

Specialties Allergy & Immunology
Pharmacology

Date 2024 Jun 3

PMID 38828869

Authors

Geeta Chahal

Jyoti Monga

Isha Rani

Shubham Saini

Manish Devgun

Asif Husain

Sukhbir Lal Khokra

Affiliations

Soon will be listed here.

Abstract

Background: Pyrazole is a well-known nucleus in the pharmacy field with a wide range of other activities in addition to anti-inflammatory and analgesic, i.e., anticonvulsant, antiviral, and anticancer activities. There are well-known marketed drugs having pyrazole moiety as celecoxib, and lonazolac as COX-II inhibitors.

Aims: We aim to synthesize better anti-inflammatory than existing ones. Thiophene is also known for its analgesic and anti-inflammatory action. Thus, the fusion of both gives better anti-inflammatory agents. In the present studies, derivatives from two series of pyrazole were prepared by reacting substituted chalcone (3a-3f) derivatives prepared from 2-acetyl thiophene. They substituted aromatic aldehydes with phenyl hydrazine to form (5a-5f) and with 2, 4-dinitro phenyl hydrazine giving compounds (6a-6f) separately.

Methods: Purified and characterized pyrazoles have been analyzed for analgesic and anti-inflammatory activities by using standard methods. Compounds 5e, 5f, and 6d were proved to be potent analgesics and series (5a-5f) was found to have anti-inflammatory action, which was further validated using docking and ADME studies.

Results: The ADME profile of synthesized compounds was found to be satisfactory.

Conclusion: The synthesized compounds can serve as lead for further drug designing.

References

Omar F, Mahfouz N, Rahman M . Design, synthesis and antiinflammatory activity of some 1,3,4-oxadiazole derivatives. Eur J Med Chem. 2011; 31(10):819-25. DOI: 10.1016/0223-5234(96)83976-6. View

Rahme E, Nedjar H . Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology (Oxford). 2007; 46(3):435-8. DOI: 10.1093/rheumatology/kel428. View

Khanna I, Weier R, Yu Y, Collins P, Miyashiro J, Koboldt C . 1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J Med Chem. 1997; 40(11):1619-33. DOI: 10.1021/jm970036a. View

Boehm J, Smietana J, Sorenson M, Garigipati R, Gallagher T, Sheldrake P . 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J Med Chem. 1996; 39(20):3929-37. DOI: 10.1021/jm960415o. View

Li J, Anderson G, Burton E, Cogburn J, Collins J, Garland D . 1,2-Diarylcyclopentenes as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. J Med Chem. 1995; 38(22):4570-8. DOI: 10.1021/jm00022a023. View

Stiller C, Hjemdahl P . Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. J Intern Med. 2022; 292(4):557-574. DOI: 10.1111/joim.13505. View

El-Malah A, Gineinah M, Deb P, Khayyat A, Bansal M, Venugopala K . Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing. Pharmaceuticals (Basel). 2022; 15(7). PMC: 9318302. DOI: 10.3390/ph15070827. View

Wang D, DuBois R . Prostaglandins and cancer. Gut. 2005; 55(1):115-22. PMC: 1856377. DOI: 10.1136/gut.2004.047100. View

Laine L . The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum. 2003; 32(3 Suppl 1):25-32. DOI: 10.1053/sarh.2002.37217. View

10.

Hawkey C . The gastroenterologist's caseload: contribution of the rheumatologist. Semin Arthritis Rheum. 1997; 26(6 Suppl 1):11-5. DOI: 10.1016/s0049-0172(97)80047-9. View

11.

Laine L, Smith R, Min K, Chen C, Dubois R . Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2006; 24(5):751-67. DOI: 10.1111/j.1365-2036.2006.03043.x. View

12.

Deeks J, Smith L, Bradley M . Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002; 325(7365):619. PMC: 126301. DOI: 10.1136/bmj.325.7365.619. View

13.

WOBER W . Comparative efficacy and safety of nimesulide and diclofenac in patients with acute shoulder, and a meta-analysis of controlled studies with nimesulide. Rheumatology (Oxford). 1999; 38 Suppl 1:33-8. DOI: 10.1093/rheumatology/38.suppl_1.33. View

14.

Lucker P, Pawlowski C, Friedrich I, Faiella F, Magni E . Double-blind, randomised, multi-centre clinical study evaluating the efficacy and tolerability of nimesulide in comparison with etodalac in patients suffering from osteoarthritis of the knee. Eur J Rheumatol Inflamm. 1994; 14(2):29-38. View

15.

Schnitzer T, Constantine G . Etodolac (Lodine) in the treatment of osteoarthritis: recent studies. J Rheumatol Suppl. 1997; 47:23-31. View

16.

NEUSTADT D . Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. J Rheumatol Suppl. 1997; 47:17-22. View

17.

Silverstein F, Faich G, Goldstein J, Simon L, Pincus T, WHELTON A . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000; 284(10):1247-55. DOI: 10.1001/jama.284.10.1247. View

18.

Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000; 343(21):1520-8, 2 p following 1528. DOI: 10.1056/NEJM200011233432103. View

19.

Schnitzer T, Burmester G, Mysler E, Hochberg M, Doherty M, Ehrsam E . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004; 364(9435):665-74. DOI: 10.1016/S0140-6736(04)16893-1. View

20.

Sharma S, Srivastava V, Kumar A . Newer N-substituted anthranilic acid derivatives as potent anti-inflammatory agents. Eur J Med Chem. 2002; 37(8):689-97. DOI: 10.1016/s0223-5234(02)01340-5. View